



Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis

Contact Us

If you would like any further information please get in touch. You can contact us by email or via our website:

www.torpedo-cf.org.uk torpedo@liverpool.ac.uk



Merry Christmas from the TORPEDO-CF team and a big Thank You to you all for your on-going support!



Hull in the spotlight

In this edition we want to highlight the fantastic efforts made by the team in Hull. The team were responsible for recruiting the 180th patient and have now successfully recruited a total of 5 patients in to the trial. Dr Kotwal described their experience of taking part in the trial "It feels good for us to be useful in this kind of research, we have experienced no real problems and the patients want to help CF research. Working on this study has strengthened relationships within the CF multidisciplinary team and our success with recruitment would not have been possible without the help and support of the physiotherapists and microbiologists. I would also like to add my praises for our research nurse who keeps us on track with paperwork and is great with patient and parents alike!"



Team at Hull enjoying TORPEDO chocolates provided as a thank you to the site that recruits every 10th patient.

Milestone Update: 200th patient recruited on 27th Nov 2014 at Alder Hey Hospital!

"Red herrings" can you spot them?

Listed below are a number of reasons sites have given for patients either not taking part in the study or not completing the study once enrolled. See if you can spot which ones are genuine exclusions / reasons:

- Poor compliance
Patient needs azithromycin
Cough/sputum sample obtained under anaesthesia
Intermediate sensitivity to trial drug/s
Original Pseudomonas aeruginosa (PsA) isolate not kept
Patient does not want to come into hospital for additional clinic visits for the study
Patient did not complete randomised treatment
Patient is transferring to a site that isn't participating in TORPEDO

The short answer is that none of the above should prevent study entry / continuation!

If you have any queries about eligibility or study discontinuation please don't hesitate to contact the study management team.

Study Update: Recruitment to continue until September 2016!

Our funders, the HTA, have recently approved a study extension to ensure that the original target of 280 recruits is reached. This means recruitment will now continue until at least the end of September 2016, with end of follow-up currently scheduled for the end of December 2017 and final study closedown scheduled for the end of June 2018.

A new version of the protocol (version 7.0) has recently been approved and pending local R&D approvals, will be made available to all sites mid-January 2015.

TORPEDO goes European!



The use of oral and intravenous antibiotics to treat new isolations of Pseudomonas aeruginosa is not only standard practice in the UK but also in many other countries in the world however up to now the study has only be open in UK sites. Well that is about to change!

The study team have recently received confirmation that sites in Italy and Sweden will be opening to recruitment for TORPEDO making it the first investigator led study of it's kind to be opened to recruitment in Europe! Watch this space for further developments.....

